KalVista Pharmaceuticals, Inc. (KALV)
| Previous Close | 12.14 |
| Open | 12.18 |
| Bid | 12.08 x 200 |
| Ask | 12.19 x 100 |
| Day's Range | 11.97 - 12.28 |
| 52 Week Range | 7.21 - 16.88 |
| Volume | |
| Avg. Volume | 781,311 |
| Market Cap | 512.588M |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England, May 02, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista’s board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 94,000 shares of KalVista common stock on May 1, 2024 as inducements material to each employee entering into employment with KalVista. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
- Business Wire
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
CAMBRIDGE, Mass. & SALISBURY, England, May 01, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced its strategic plans for fiscal year 2025, beginning May 1, including for sebetralstat, the Company’s investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema (HAE).
- Business Wire
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
CAMBRIDGE, Mass. & SALISBURY, England, April 22, 2024--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the Company’s Board of Directors, effective immediately. Mr. Fairey was most recently the Chief Commercial Officer at MyoKardia, Inc., a clinical stage biopharmaceutical company, and is a bus
